全文获取类型
收费全文 | 517286篇 |
免费 | 38201篇 |
国内免费 | 11139篇 |
专业分类
耳鼻咽喉 | 6241篇 |
儿科学 | 9903篇 |
妇产科学 | 11556篇 |
基础医学 | 73836篇 |
口腔科学 | 14145篇 |
临床医学 | 46976篇 |
内科学 | 97440篇 |
皮肤病学 | 10021篇 |
神经病学 | 33899篇 |
特种医学 | 18647篇 |
外国民族医学 | 147篇 |
外科学 | 73620篇 |
综合类 | 33044篇 |
现状与发展 | 30篇 |
一般理论 | 76篇 |
预防医学 | 27316篇 |
眼科学 | 12794篇 |
药学 | 47196篇 |
122篇 | |
中国医学 | 9966篇 |
肿瘤学 | 39651篇 |
出版年
2023年 | 2882篇 |
2022年 | 6885篇 |
2021年 | 9763篇 |
2020年 | 6896篇 |
2019年 | 7365篇 |
2018年 | 9335篇 |
2017年 | 7893篇 |
2016年 | 7752篇 |
2015年 | 10206篇 |
2014年 | 13301篇 |
2013年 | 14781篇 |
2012年 | 20373篇 |
2011年 | 21215篇 |
2010年 | 13971篇 |
2009年 | 12121篇 |
2008年 | 16927篇 |
2007年 | 17752篇 |
2006年 | 17013篇 |
2005年 | 15477篇 |
2004年 | 13578篇 |
2003年 | 13252篇 |
2002年 | 12183篇 |
2001年 | 31320篇 |
2000年 | 31351篇 |
1999年 | 25999篇 |
1998年 | 6718篇 |
1997年 | 5974篇 |
1996年 | 5046篇 |
1995年 | 4641篇 |
1994年 | 4161篇 |
1993年 | 3576篇 |
1992年 | 16896篇 |
1991年 | 15580篇 |
1990年 | 14853篇 |
1989年 | 14594篇 |
1988年 | 13141篇 |
1987年 | 12521篇 |
1986年 | 11539篇 |
1985年 | 10689篇 |
1984年 | 7233篇 |
1983年 | 5862篇 |
1982年 | 2963篇 |
1979年 | 5650篇 |
1978年 | 3529篇 |
1977年 | 3172篇 |
1975年 | 2755篇 |
1974年 | 3216篇 |
1973年 | 2992篇 |
1972年 | 2931篇 |
1971年 | 2895篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
目的探讨定量测定肝癌患者血清12种肿瘤标志物的临床意义。方法用蛋白芯片技术定量测定42例正常人、46例肝癌、41例肝炎和23例肝硬化患者血清12种肿瘤标志物的变化并对检测效果进行评价。结果42例正常人CA-199(KU/L)、NSE(g/L)、CEA(g/L)、CA-242(KU/L)、Ferritin(g/L)、β-HCG(g/L)、AFP(g/L)、f-PSA(g/L)、PSA(g/L)、CA-125(KU/L)、HGH(g/L)和CA-153(KU/L)的含量分别为12.42±10.62、2.22±1.43、1.28±1.20、5.72±5.73、91.17±79.43、0.64±0.34、2.96±3.93、0.13±0.11、0.61±1.40、5.46±9.65、1.61±2.40、9.83±9.51;46例肝癌患者血清12种肿瘤标志物含量依次为:35.09±39.50、2.83±4.13、2.98±8.72、8.47±23.42、157.50±129.77、0.72±0.72、87.58±63.27、0.15±0.19、0.58±1.88、56.34±102.02、3.63±4.57、15.65±51.09;41例肝炎患者其含量依次为:76.23±96.57、4.12±4.94、2.06±3.92、4.68±6.99、298.76±326.82、1.00±0.74、63.16±91.76、0.11±0.006、0.27±0.94、18.57±36.60、3.63±4.00、6.13±6.86;23例肝硬化患者其含量依次为:49.85±75.60、5.47±14.97、1.71±1.77、12.44±34.55、278.32±326.82、0.70±0.54、52.89±98.28、0.22±0.21、2.24±4.36、111.50±191.99、2.15±0.99、10.51±15.79。该蛋白芯片测定的敏感性为50.0%,特异性为64.2%,阳性预测值为37.7%,阴性预测值为74.7%。结论采用蛋白芯片技术同时测定患者血清多种肿瘤标志物,对普查肿瘤和临床疗效观察有较好应用价值。 相似文献
992.
N Tonami K Yokoyama J Taki K Hisada Y Watanabe T Takashima A Nonomura 《Journal of nuclear medicine》1991,32(12):2284-2285
A case of radiologically occult lung cancer is presented in which 201TI SPECT of the chest clearly delineated the involved area. A 66-yr-old man underwent chest screening examinations for asymptomatic smokers and presented a positive sputum cytology for lung cancer. Conventional chest x-ray, tomography of computed radiography, and a CT scan failed to locate the lesion in the lung. Thallium-201 SPECT, however, was successful in depicting the area of the involvement. 相似文献
993.
Longitudinal Analysis of Severe Acute Respiratory Syndrome (SARS) Coronavirus-Specific Antibody in SARS Patients
下载免费PDF全文
![点击此处可从《Clinical and Vaccine Immunology : CVI》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Shan-Chwen Chang Jann-Tay Wang Li-Min Huang Yee-Chun Chen Chi-Tai Fang Wang-Huei Sheng Jiun-Ling Wang Chong-Jen Yu Pan-Chyr Yang 《Clinical and Vaccine Immunology : CVI》2005,12(12):1455-1457
The serum antibodies to severe acute respiratory syndrome (SARS) coronavirus of 18 SARS patients were checked at 1 month and every 3 months after disease onset. All of them except one, who missed blood sampling at 1 month, tested positive for the immunoglobulin G (IgG) antibody at 1 month. Fifteen out of 17 tested positive for the IgM antibody at 1 month. The serum IgM antibody of most patients became undetectable within 6 months after the onset of SARS. The IgG antibody of all 17 patients, whose serum was checked 1 year after disease onset, remained positive. 相似文献
994.
对不孕症患者进行碘化油输卵管造影检查是临床上经常需要做的一种检查,以往施行输卵管碘化油造影是在X线照射下,由于造影需要时间较长,医患双方都会接受大量X线照射,不利于身体健康。我院自2002年1月~2003年3月,对30例不孕症患者,利用B超经腹壁,在实时观察引导下行碘化油输卵管造影术,现总结报告如下。1材料与方法本组患者年龄在25~45岁,均经临床妇科检查及B超常规检查,经输卵管通液及药物治疗无效者。其中原发不孕5例,继发不孕25例。采用东芝公司的SSH-140A型超声诊断仪,探头频率3·75MHz。窥阴器、宫颈钳、宫颈导管、20ml或30ml注射器… 相似文献
995.
996.
997.
998.
999.
Hasan Yüksel Ali Riza Odaba?i Selda Demircan Aslihan Karul Leyla Didem Kozaci Kutsi K?seo?lu Kadir Kizilkaya Okay Ba?ak 《Gynecological endocrinology》2006,22(7):381-387
AIM: To evaluate the effects of oral continuous 17beta-estradiol plus norethisterone acetate (E2/NETA) replacement therapy on abdominal subcutaneous fat, serum leptin level (SLL) and body composition in postmenopausal women. MATERIALS AND METHODS: A 6-month, prospective, randomized, double-blind and placebo-controlled study was conducted. Forty-three healthy naturally postmenopausal women aged 43-65 years were randomly assigned to receive E2/NETA (2 mg E2 plus 1 mg NETA, n = 22) or placebo (n = 21). Fasting SLL by enzyme-linked immunosorbent assay, subcutaneous abdominal fat thickness (STh) by ultrasound and the anthropometric indices of body weight (BW), body mass index (BMI), waist and hip circumference (WC, HC) and waist-to-hip ratio (WHR) were recorded at the beginning and the end of the study. RESULTS: After 6 months of therapy, BW and SLL increased in the placebo group (p = 0.043 and 0.033, respectively). WC, HC and STh decreased significantly in the E2/NETA group (p = 0.002, 0.006 and 0.000, respectively) and they were also significantly lower in women receiving E2/NETA than in women taking placebo (p = 0.000, 0.034 and 0.000, respectively). At baseline, SLL and STh were positively correlated with all anthropometric indices except WHR. CONCLUSION: Oral continuous combined regimen of E2/NETA significantly reduced central fat accumulation as assessed by WC and STh, and attenuated the increase in SLL. The observed changes in SLL were highly and positively related to changes in STh. The oral continuous combined E2/NETA regimen appears to have protective effects on cardiovascular function and probably on metabolic diseases by its slimming effect upon WC in postmenopausal women. 相似文献
1000.
Arsenic trioxide–loaded, microemulsion-enhanced cytotoxicity on MDAH 2774 ovarian carcinoma cell line 总被引:2,自引:0,他引:2
M.C. TEREK B. KARABULUT† N. SELVI‡ L. AKMAN Y. KARASULU§ I. OZGUNEY§ A.U. SANLI† R. USLU† & A. OZSARAN 《International journal of gynecological cancer》2006,16(2):532-537
The antiproliferative effect of As(2)O(3)-loaded microemulsion (As(2)O(3)-M) on human MDAH 2774 ovarian cancer cells was compared with a regular solution of the As(2)O(3). We used MDAH 2774 as model cell lines for ovarian cancer. The (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide) (XTT) and trypane blue dye exclusion tests were used to evaluate cytotoxicity. Apoptotic effect of solutions was evaluated using cell death detection kit. Standard microemulsion formulation used in this experiment contains 5 x 10(-6) M As(2)O(3). It was clearly demonstrated that As(2)O(3)-M had a significant cytotoxic effect on MDAH 2774 cell line, and the cytotoxic effect of As(2)O(3)-M was significantly higher than that of regular As(2)O(3) solutions. Even approximately 6000 times diluted microemulsion formulation loaded with 5 x 10(-6) M As(2)O(3) showed a cytotoxic effect. As a result, this diluted concentration (approximately 8 x 10(-10) M) was found to be approximately 6000 times more effective than regular As(2)O(3) solutions (5 x 10(-6) M). Moreover, this diluted concentration resulted in 1.5-fold enhancement of apoptosis. According to the in vitro cytotoxicity studies, we concluded that by incorporating As(2)O(3) into the microemulsion (As(2)O(3)-M), which is a new drug carrier system, it is possible to increase antiproliferative effect of regular As(2)O(3) on MDAH 2774 cells. Translating these results to in vivo conditions would open new windows in the treatment of ovarian cancer. 相似文献